Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Milciclib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Pha-848125, 802539-81-7, Pha 848125, Milciclib [inn], Milciclib (pha-848125), Pha848125
    Molecular Formula
    C25H32N8O
    Molecular Weight
    460.6  g/mol
    InChI Key
    RXZMYLDMFYNEIM-UHFFFAOYSA-N
    FDA UNII
    688000M8S8
    Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and tropomyosin receptor kinase A (TRKA), with potential antineoplastic activity. CDK2/TRKA inhibitor PHA-848125 AC potently inhibits cyclin-dependent kinase 2 (CDK2) and exhibits activity against other CDKs including CDK1 and CDK4, in addition to TRKA. Inhibition of these kinases may result in cell cycle arrest and apoptosis of tumor cells that express these kinases. CDKs are serine/threonine kinases involved in regulation of the cell cycle and may be overexpressed in some cancer cell types. The neurotrophin receptor TRKA is mutated in a variety of cancer cell types.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5H-pyrazolo[4,3-h]quinazoline-3-carboxamide
    2.1.2 InChI
    InChI=1S/C25H32N8O/c1-25(2)14-16-15-27-24(29-20(16)22-19(25)21(23(34)26-3)30-32(22)5)28-17-6-8-18(9-7-17)33-12-10-31(4)11-13-33/h6-9,15H,10-14H2,1-5H3,(H,26,34)(H,27,28,29)
    2.1.3 InChI Key
    RXZMYLDMFYNEIM-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1(CC2=CN=C(N=C2C3=C1C(=NN3C)C(=O)NC)NC4=CC=C(C=C4)N5CCN(CC5)C)C
    2.2 Other Identifiers
    2.2.1 UNII
    688000M8S8
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Miliciclib

    2. N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1h-pyrazolo(4,3-h)quinazoline-3-carboxamide

    3. Pha 848125

    4. Pha-848125

    5. Pha-848125ac

    6. Pha848125

    2.3.2 Depositor-Supplied Synonyms

    1. Pha-848125

    2. 802539-81-7

    3. Pha 848125

    4. Milciclib [inn]

    5. Milciclib (pha-848125)

    6. Pha848125

    7. 4,5-dihydro-n,1,4,4-tetramethyl-8-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide

    8. Mmv676602

    9. N,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5h-pyrazolo[4,3-h]quinazoline-3-carboxamide

    10. 688000m8s8

    11. 1h-pyrazolo(4,3-h)quinazoline-3-carboxamide, 4,5-dihydro-n,1,4,4-tetramethyl-8-((4-(4-methyl-1-piperazinyl)phenyl)amino)-

    12. N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide

    13. N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1h-pyrazolo(4,3-h)quinazoline-3-carboxamide

    14. N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide

    15. Unii-688000m8s8

    16. 4,5-dihydro-n,1,4,4-tetramethyl-8-((4-(4-methyl-1-piperazinyl)phenyl)amino)-1h-pyrazolo(4,3-h)quinazoline-3-carboxamide

    17. Milciclib; Pha 848125

    18. Mls006011032

    19. Schembl619139

    20. Chembl564829

    21. Gtpl7938

    22. Pha-848125 - Milciclib

    23. Bdbm31545

    24. Dtxsid80230186

    25. Bcpp000109

    26. Hms3656p21

    27. Bcp01918

    28. Ex-a2135

    29. Nsc800792

    30. S2751

    31. Zinc53119602

    32. Akos030231455

    33. Ccg-269340

    34. Cs-0579

    35. Nsc-800792

    36. Sb16657

    37. Ncgc00346673-01

    38. Ncgc00346673-05

    39. Ac-35945

    40. As-56203

    41. Hy-10424

    42. Smr004700646

    43. Db-075668

    44. Ft-0732566

    45. Sw219949-1

    46. D82291

    47. Pyrazolo[4,3-h]quinazoline-3-carboxamide, 28

    48. Sr-05000022565

    49. J-523919

    50. Sr-05000022565-1

    51. Pha-848125,cas:802539-81-7

    52. Q27086363

    53. 8-[4-(4-methyl-piperazin-1-yl)-phenylamino]-1,4,4-trimethyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxylic Acid Methylamide

    54. N,1,4,4-tetramethyl-8-[[4-(4-methylpiperazin-1-yl)phenyl]amino]-5h-pyrazolo[4,5-h]quinazoline-3-carboxamide

    2.4 Create Date
    2007-08-27
    3 Chemical and Physical Properties
    Molecular Weight 460.6 g/mol
    Molecular Formula C25H32N8O
    XLogP32.8
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count4
    Exact Mass460.26990767 g/mol
    Monoisotopic Mass460.26990767 g/mol
    Topological Polar Surface Area91.2 Ų
    Heavy Atom Count34
    Formal Charge0
    Complexity718
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.